Core--Retroviral and AAV Vector

核心--逆转录病毒和AAV载体

• 批准号: 7337074
• 负责人: Arthur Dusty Miller
• 金额: $ 15.81万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7337074
• 关键词: Adenovirus Vector; Animals; Clinical; Condition; Consultations; Cultured Cells; Development; Ensure; Evaluation; Gene Expression; Gene Transfer; Generations; Genes; Goals; Human; Human Resources; Laboratories; Lentivirus Vector; Maintenance; Methodology; Molecular Biology; Production; Property; Protocols documentation; Rate; Research; Research Personnel; Secure; Services; Techniques; Technology; Testing; Tissues; Training; United States Food and Drug Administration; Viral Vector; Virus; adeno-associated viral vector; base; design; gene therapy; gene transfer vector; improved; in vivo; interest; investigator training; novel strategies; technology development; vector; virology

The original goal of the Vector Core was to provide Center investigators with services relating to the development of gene transfer vectors required for clinical gene therapy protocols. This included providing vectors available with current technology and the development of new approaches based upon investigator needs. The Vector Core would be responsible for maintaining good laboratory practices consistent with RAC and FDA requirements for vectors to be used in humans, and would assist investigators in securing approval for gene therapy trials.

向量核心的最初目标是为中心调查人员提供服务 涉及临床基因治疗方案所需的基因转移载体的开发。 这包括提供现有技术可用的载体，以及开发新的 基于调查员需求的方法。向量核心将负责 保持良好的实验室做法，与RAC和FDA对用于人类的载体的要求保持一致，并将帮助研究人员获得基因治疗试验的批准。